Thyroid Hormone Receptor Interactor 11 (TRIP11) (AA 1292-1926) antibody

Catalog No. ABIN7870449

The Rabbit Polyclonal anti-Thyroid Hormone Receptor Interactor 11 antibody is suitable to detect Thyroid Hormone Receptor Interactor 11 in samples from Human and Rat. It has been validated for WB and ELISA.

Quick Overview for Thyroid Hormone Receptor Interactor 11 (TRIP11) (AA 1292-1926) antibody (ABIN7870449)

Target: Thyroid Hormone Receptor Interactor 11 (TRIP11)

Reactivity: Human, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: Un-conjugated

Application: Western Blotting (WB), ELISA

Product Details

Binding Specificity: AA 1292-1926

Purpose: TRIP11 Antibody / Thyroid receptor-interacting protein 11 / GMAP-210

Purification: Immunogen affinity purified

Immunogen: E.coli-derived human GMAP-210/TRIP11 recombinant protein (Position: Q1292-R1926) was used as the immunogen for the TRIP11 antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the TRIP11 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the TRIP11 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details

Target: Thyroid Hormone Receptor Interactor 11 (TRIP11)

Alternative Name: TRIP11

Background: TRIP11 antibody detects Thyroid receptor-interacting protein 11 (also known as GMAP-210), a large coiled-coil Golgi microtubule-associated protein involved in maintaining Golgi structure and vesicle trafficking. Encoded by the TRIP11 gene on chromosome 14q32.12, this protein functions as a tethering factor that anchors vesicles to the Golgi membrane, facilitating directional transport between the endoplasmic reticulum (ER) and Golgi apparatus. GMAP-210 is essential for Golgi organization, ciliary assembly, and protein glycosylation, linking cytoskeletal dynamics to secretory pathway regulation.

TRIP11/GMAP-210 contains an N-terminal GRAB domain that interacts with the small GTPase ARF1 and a C-terminal acidic motif that binds to vesicular membranes. These dual binding regions enable the protein to bridge vesicles and the Golgi surface, stabilizing Golgi ribbon structure and promoting vesicle docking. In addition, its extended coiled-coil conformation provides a physical scaffold that organizes Golgi cisternae and positions them relative to the microtubule network. Depletion or mutation of GMAP-210 results in Golgi fragmentation, defective cargo trafficking, and impaired ciliary protein transport.

The TRIP11 antibody is widely used in cell biology, neurobiology, and developmental research to study Golgi morphology and vesicle tethering. Western blot analysis typically identifies a 210 kilodalton band corresponding to full-length GMAP-210, while immunofluorescence reveals Golgi-localized perinuclear staining. This antibody enables detailed visualization of Golgi organization, vesicle docking, and intracellular transport pathways.

Mutations in TRIP11 cause achondrogenesis type 1A, a lethal skeletal dysplasia resulting from defective protein secretion and ciliary dysfunction. Beyond skeletal disease, altered expression of GMAP-210 affects neural development, epithelial polarization, and secretion of extracellular matrix proteins. The TRIP11 antibody supports research into Golgi-associated transport, ciliogenesis, and protein trafficking disorders. NSJ Bioreagents provides this antibody validated for its applications, ensuring precise detection in studies of Golgi dynamics and secretory pathway organization.

UniProt: Q15643